Published in J Health Organ Manag on January 01, 2012
Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis. Cost Eff Resour Alloc (2014) 1.18
Health technology assessments as a mechanism for increased value for money: recommendations to the Global Fund. Global Health (2013) 0.93
Incorporating cost-effectiveness data in a fair process for priority setting efforts Comment on "Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden". Int J Health Policy Manag (2015) 0.91
Public preferences for engagement in Health Technology Assessment decision-making: protocol of a mixed methods study. BMC Med Inform Decis Mak (2015) 0.91
Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study. Health Res Policy Syst (2015) 0.81
Preferences for engagement in health technology assessment decision-making: a nominal group technique with members of the public. BMJ Open (2016) 0.78
Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet (2009) 16.12
The limitations of "vulnerability" as a protection for human research participants. Am J Bioeth (2004) 14.06
AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ (2010) 8.73
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
No surgical innovation without evaluation: the IDEAL recommendations. Lancet (2009) 5.57
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ (2009) 3.65
Oversight of human participants research: identifying problems to evaluate reform proposals. Ann Intern Med (2004) 3.58
Legal and ethical implications of NICE guidance aimed at optimising organ transplantation after circulatory death. Clin Med (2013) 3.19
Evaluation and stages of surgical innovations. Lancet (2009) 3.04
Challenges in evaluating surgical innovation. Lancet (2009) 2.86
AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol (2010) 2.51
Disinvestment from low value clinical interventions: NICEly done? BMJ (2011) 2.39
How to formulate research recommendations. BMJ (2006) 2.38
Evidence-based decision making: when should we wait for more information? Health Aff (Millwood) (2008) 2.13
The second wave: Toward responsible inclusion of pregnant women in research. Int J Fem Approaches Bioeth (2008) 2.07
Healthy decisions: towards uncertainty tolerance in healthcare policy. Pharmacoeconomics (2015) 2.01
Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol (2014) 1.65
Science and law. Integrity in international stem cell research collaborations. Science (2006) 1.64
A collaboratively-derived science-policy research agenda. PLoS One (2012) 1.63
Identifying existing health care services that do not provide value for money. Med J Aust (2009) 1.59
AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med (2010) 1.46
National Institute for Health and Clinical Excellence appraisal and ageism. J Med Ethics (2012) 1.39
Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand. Value Health (2012) 1.35
Ethics: Moral issues of human-non-human primate neural grafting. Science (2005) 1.35
Addressing low-risk comparative effectiveness research in proposed changes to US federal regulations governing research. JAMA (2012) 1.26
Social values in health priority setting: a conceptual framework. J Health Organ Manag (2012) 1.25
Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program. Pharmacoeconomics (2009) 1.23
Searching for cost effectiveness thresholds in the NHS. Health Policy (2009) 1.23
Controversy and quality improvement: lingering questions about ethics, oversight, and patient safety research. Jt Comm J Qual Patient Saf (2008) 1.22
Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat (2011) 1.20
Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment. BMC Health Serv Res (2010) 1.18
The economic impact of alcohol consumption: a systematic review. Subst Abuse Treat Prev Policy (2009) 1.17
Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Q (2009) 1.12
Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand. BMC Health Serv Res (2010) 1.12
Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics. PLoS One (2012) 1.11
Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics (2011) 1.11
The Global Rating Scale complements the AGREE II in advancing the quality of practice guidelines. J Clin Epidemiol (2011) 1.11
Long-term acute care hospitals: a clinical, economic, and ethical dilemma. Med Care (2013) 1.09
Consideration of social values in the establishment of accountable care organizations in the USA. J Health Organ Manag (2012) 1.08
Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service? J Health Serv Res Policy (2007) 1.08
Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia (2013) 1.07
Universal coverage and its impact on reproductive health services in Thailand. Reprod Health Matters (2002) 1.07
Factors that affect infertility patients' decisions about disposition of frozen embryos. Fertil Steril (2006) 1.07
Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable? Value Health (2010) 1.06
Universal coverage of renal dialysis in Thailand: promise, progress, and prospects. BMJ (2013) 1.06
Engaging the public in healthcare decision-making: quantifying preferences for healthcare through citizens' juries. BMJ Open (2014) 1.04
Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand. Health Res Policy Syst (2012) 1.04
Health related quality of life among patients with tuberculosis and HIV in Thailand. PLoS One (2012) 1.02
Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. J R Soc Med (2007) 1.01
Cost-effective public health guidance: asking questions from the decision-maker's viewpoint. Health Econ (2008) 1.01
Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence. J Public Health Med (2002) 1.00
Reducing ineffective practice: challenges in identifying low-value health care using Cochrane systematic reviews. J Health Serv Res Policy (2013) 1.00
Reviewing the evidence on effectiveness and cost-effectiveness of HIV prevention strategies in Thailand. BMC Public Health (2010) 0.99
Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health (2008) 0.98
Using health technology assessment for informing coverage decisions in Thailand. J Comp Eff Res (2012) 0.97
Categorizing empirical research in bioethics: why count the ways? Am J Bioeth (2009) 0.97
Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand. Value Health (2012) 0.97
A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res (2010) 0.94
Pluripotent stem cell-derived gametes: truth and (potential) consequences. Cell Stem Cell (2009) 0.94
Health technology reassessment: the art of the possible. Int J Technol Assess Health Care (2013) 0.94
Inequalities in health, inequalities in health care: four generations of discussion about justice and cost-effectiveness analysis. Kennedy Inst Ethics J (2000) 0.92
"Special scrutiny": a targeted form of research protocol review. Ann Intern Med (2004) 0.92
Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics (2010) 0.92
NICE's social value judgements about equity in health and health care. Health Econ Policy Law (2012) 0.91
Coverage with evidence development: a very good beginning, but much to be done. Commentary to Hutton et al. Int J Technol Assess Health Care (2007) 0.91
Government use licenses in Thailand: an assessment of the health and economic impacts. Global Health (2011) 0.90
Evidence-informed evidence-making. J Health Serv Res Policy (2008) 0.89
Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health (2013) 0.89
Pregnant women's attitudes toward the abortion of defective fetuses. Popul Environ (1983) 0.88
Social value judgments in healthcare: a philosophical critique. J Health Organ Manag (2012) 0.88
Improving health system quality in low- and middle-income countries that are expanding health coverage: a framework for insurance. Int J Qual Health Care (2013) 0.88
Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand. BMC Public Health (2011) 0.87
Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine (2013) 0.86
The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand. J Med Assoc Thai (2008) 0.86
CoCanCPG. Coordination of cancer clinical practice in Europe. Tumori (2008) 0.86
The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. J Cereb Blood Flow Metab (2008) 0.86
The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales. Clin Cancer Res (2011) 0.85
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res (2013) 0.85
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res (2014) 0.85
Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections. BMC Pediatr (2013) 0.84
The economic costs of alcohol consumption in Thailand, 2006. BMC Public Health (2010) 0.84
Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research. Int J Technol Assess Health Care (2009) 0.84
Determining the value of drugs--the evolving British experience. N Engl J Med (2011) 0.84
The UK Freedom of Information Act (2000) in healthcare research: a systematic review. BMJ Open (2013) 0.83
Efficiency or equity: value judgments in coverage decisions in Thailand. J Health Organ Manag (2012) 0.83
Mortality attributable to seasonal influenza A and B infections in Thailand, 2005-2009: a longitudinal study. Am J Epidemiol (2015) 0.83
Comparative effectiveness research: the experience of the National Institute for Health and Clinical Excellence. J Clin Oncol (2012) 0.82
Comparative effectiveness research: a useful tool. Health Aff (Millwood) (2009) 0.82
Economic costs of obesity in Thailand: a retrospective cost-of-illness study. BMC Health Serv Res (2014) 0.82
Making health technology assessment information available for decision making: the development of a Thai database. J Med Assoc Thai (2008) 0.81
Economic impact on health-care costs related to major diseases including HIV/AIDS due to alcohol drinking among Thai populations. Value Health (2010) 0.80
Infective endocarditis. NICE calls for a register. BMJ (2011) 0.80
The influence of HIV serostatus on physicians' clinical decisions. AIDS Public Policy J (1994) 0.80
NICE was explicit in constructing guideline. BMJ (2007) 0.80